Skip to main content

Table 3 Therapeutic support at the entry date and associations with case status (death)

From: Clinical characteristics and outcomes in adult cystic fibrosis patients with severe lung disease in Porto Alegre, southern Brazil

 

All

Death

Survival

Transplant

HR (95% CI)

p-values

Subjects (n)

39

20 (51.3)

3 (7.7)

16 (41.0)

  

Dornase alfa (yes)

39 (100.0)

20 (100.0)

3 (100.0)

16 (100.0)

Colistin inhalation (yes)

38 (97.4)

20 (100.0)

2 (66.7)

16 (100.0)

0.05 (0.0–472.26)

0.511

Tobramycin inhalation (yes)

19 (48.7)

15 (75.0)

1 (33.3)

3 (18.8)

3.82 (1.38–10.60)

0.010

Azithromycin (yes)

33 (84.6)

16 (80.0)

3 (100.0)

14 (87.5)

1.32 (0.44–4.01)

0.622

Oxygen therapy (yes)

19 (48.7)

10 (50.0)

3 (100.0)

6 (37.5)

0.55 (0.22–1.36)

0.191

Pulmonary Exacerbations in the last year, median IR)

3 (1)

3 (1)

2(0)

3 (3)

0.86 (0.61–1.21

0.392

Hospital admission in the last year (n), median (IR)

2.1 (2.0)

2.0 (2.0)

0 (0.0)

2.0 (1.0)

1.21 (0.91–1.61)

0.198

NIMV in the last year (yes)

6 (15.4)

2 (10.0)

1 (33.3)

3 (18.8)

0.73 (0.17–3.23)

0.692

ICU admission in the last year (yes)

7 (17.9)

2 (10.0)

1 (33.3)

4 (25.0)

0.75 (0.17–3.43)

0.713

Mechanical ventilation (yes)

5 (12.8)

2 (10.0)

1 (33.3)

2 (12.5)

2.33 (0.51–10.8)

0.278

  1. Data are presented as n (%), median ± standard deviation or median (interquartile range). Hazard ratios (HRs) were derived from Cox regression models. CI confidence interval, NIMV non-invasive mechanical ventilation, ICU intensive care unit